Obesity Market to Showcase Robust Growth at a CAGR of 23% by 2032 | DelveInsight

News provided by

Sep 14, 2022, 08:30 ET

The obesity market is expected to grow significantly owing to an increase in upcoming novel treatment options, increasing market size due to increasing prevalence, and increasing global healthcare investment and funding.

LAS VEGAS, Sept. 14, 2022 /PRNewswire/ -- DelveInsight's Obesity Market Insights report includes a comprehensive understanding of current treatment practices, obesity emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Obesity Market Report

As per DelveInsight analysis, the obesity market size in the 7MM was approximately USD 1,052 million in 2021.
As per the estimates, the total obesity prevalence among adults in the 7MM was approximately 182 million in 2021.
Leading obesity companies such as Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu Hengrui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others are developing novel obesity drugs that can be available in the obesity market in the upcoming years.
The obesity therapies in the pipeline include Semaglutide oral, Tirzepatide, Cotadutide, BI 456906, RZL-012, NNC0174-0833, Pemvidutide, Tesomet, Xla1, IBI362, HSG4112, S-237648, ARD-101, LY 3437943, Leucine/sildenafil, MBL949, TG103, SHR20004, CT-868, PF-06882961, NNC0165-1875, XW 003, LY3502970, EMP16-01, NNC-0480-0389, NNC0247 0829, and others.
The dynamics of the obesity market are anticipated to change during the forecast period, owing to the expected launch of new therapies.

Discover which therapies are expected to grab major obesity market share @Obesity Market Report

Obesity Overview

Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as behavior and culture, have a direct influence.

Obesity symptoms extend beyond increased body fat, and it can cause skin problems, shortness of breath, difficulty sleeping, and other symptoms. Some symptoms are even known to raise a person's likelihood of developing certain diseases and disorders. These can be life-threatening or even fatal in some situations.

Obesity Epidemiology Segmentation

As per DelveInsight estimates, there were approximately 182 million prevalent cases of obesity in adults in the 7MM in 2021.

Among the 7MM, the EU5 had recorded the highest obesity prevalence in 2021.

The obesity market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total prevalent cases of obesity
Total Obesity patients seeking help
Total treated cases of obesity

Download the report to understand which factors are driving obesity epidemiology trends @Obesity Epidemiological Insights

Obesity Treatment Market

Obesity treatments include losing weight through healthy eating, increasing physical activity, and making other lifestyle changes. Some people may benefit from weight-management programs to lose or maintain their weight, and some obese people cannot lose enough weight to improve their health or maintain weight loss.

Moreover, when a patient has not been able to lose weight through diet and exercise and meets one of the following criteria, the doctor may consider a weight-loss drug for the patient: body mass index (BMI) greater than 30 or BMI greater than 27 and the patient has a serious medical problem related to obesity, such as diabetes or high blood pressure. Prescription medications for treating obesity and overweight work in a variety of ways. Some medications, for example, may help you feel less hungry or full sooner, and other medications may make it more difficult for the body to absorb fat from food.

Furthermore, the FDA-approved obesity drugs currently available on the market for treatment include Contrave (Currax Pharmaceuticals), Saxenda (Novo Nordisk), Wegovy (Novo Nordisk), Qsymia, (Vivus/IEH Biopharma), Xenical (Hoffmann-La Roche/H2 Pharma), Imcivree (Rhythm Pharmaceuticals), and others.

To know more about obesity treatment options, visit @New Treatment for Obesity

Obesity Pipeline Therapies and Key Companies

Semaglutide oral: Novo Nordisk
Tirzepatide: Eli Lilly and Company
Cotadutide: MedImmune
BI 456906: Boehringer Ingelheim
RZL-012: Raziel Therapeutics
NNC0174-0833: Novo Nordisk
Pemvidutide: Altimmune
Tesomet: Saniona
Xla1: YSOPIA Bioscience
IBI362: Innovent Biologics
HSG4112: Glaceum
S-237648: Shionogi
ARD-101: Aardvark Therapeutics
LY 3437943: Eli Lilly and Company
Leucine/sildenafil: NuSirt Biopharma
MBL949: Novartis
TG103: CSPC Baike (Shandong) Biopharmaceutical
SHR20004: Jiangsu HengRui Medicine
CT-868: Carmot Therapeutics
PF-06882961: Pfizer
NNC0165-1875: Novo Nordisk
XW 003: Sciwind Biosciences
LY3502970: Eli Lilly and Company
EMP16-01: Empros Pharma
NNC-0480-0389: Novo Nordisk
NNC0247 0829: Novo Nordisk

Learn more about the FDA-approved obesity drugs @Drugs for Obesity Treatment

Obesity Market Dynamics

Obesity management and its associated comorbidities have evolved. Obesity treatment currently aims to reduce body weight and fat percentage to prevent the onset of obesity-related health problems and improve the patient's overall health. More companies are focusing on the upcoming obesity therapeutic pipeline to address the challenges mentioned above.

Moreover, obesity cases in children and adults have increased due to sedentary lifestyles and other risk factors associated with obesity, accelerating obesity market growth. Furthermore, many government and non-government organizations are attempting to raise awareness of obesity among patients. As a result, patients will seek appropriate treatment, further expanding the obesity market.

However, certain factors are slowing down the obesity market growth. The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the obesity market growth.

Moreover, there is a significant disparity in the disease staging systems used in the obesity treatment landscape. As a result, there is a need to agree on when and if different staging systems should be used. Furthermore, obesity-related comorbidities necessitate additional medications and treatments, complicating obesity management and increasing costs and patient adherence.

Scope of the Obesity Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Obesity Companies: Hoffmann-La Roche, H2 Pharma, Vivus, IEH Biopharma, Orexigen Therapeutics, Currax, Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others
Key Obesity Therapies: Semaglutide oral, Tirzepatide, Cotadutide, BI 456906, RZL-012, NNC0174-0833, Pemvidutide, Tesomet, Xla1, IBI362, HSG4112, S-237648, ARD-101, LY 3437943, Leucine/sildenafil, MBL949, TG103, SHR20004, CT-868, PF-06882961, NNC0165-1875, XW 003, LY3502970, EMP16-01, NNC-0480-0389, NNC0247 0829, and others
Therapeutic Assessment: Obesity current marketed and emerging therapies
Obesity Market Dynamics: Obesity market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Obesity Market Access and Reimbursement

Discover more about drugs for obesity in development @Obesity Clinical Trials

Table of Contents

1.	Obesity Market Key Insights
2.	Obesity Market Report Introduction
3.	Obesity Market Overview at a Glance
4.	Obesity Market Executive Summary
5.	Disease Background and Overview
6.	Obesity Treatment and Management
7.	Obesity Epidemiology and Patient Population
8.	Patient Journey
9.	Obesity Marketed Drugs
10.	Obesity Emerging Drugs
11.	Seven Major Obesity Market Analysis
12.	Obesity Market Outlook
13.	Potential of Current and Emerging Therapies
14.	KOL Views
15.	Obesity Market Drivers
16.	Obesity Market Barriers
17.	Unmet Needs
18.	SWOT Analysis
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Get in touch with our business executive @Healthcare Due Diligence Services

Related Reports

Obesity Epidemiology Forecast

Obesity Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and obesity epidemiology trends.

Obesity Pipeline

Obesity Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key obesity companies, including Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, among others.

Hypothalamic Obesity Market

Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.

Hypothalamic Obesity Pipeline

Hypothalamic Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others.

HET Obesity/POMC Deficiency Obesity Pipeline

HET Obesity/POMC Deficiency Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.

HET Obesity/POMC Deficiency Obesity Market

HET Obesity/POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others.

Other Trending Reports

Related Healthcare Blogs

Obesity: A Global Concern

Weight Loss and Obesity Market

Obesity Treatment Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP